Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Healthcare Bill's Failure Could Have Unpleasant Ripple Effects For Pharma

Executive Summary

Having sat on the sidelines during the unsuccessful effort to repeal and replace Obamacare, the pharma industry may find the rest of its legislative agenda, from taxes to even user fee reauthorization, could become more difficult.


Related Content

PhRMA And Trump: 'Go Boldly,' Or Tread Carefully?
User Fee Bill Could Become Ensnared In US Abortion Politics
US FDA Faces Hiring Slowdown, Funding Cuts In Trump's FY 17 Plan
Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
User Fees: Should US FDA Incur Penalties For Missed Deadlines?
Medicaid Block Grants: Allowing More State Flexibility To Limit Rx Coverage?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts